Amarin Corporation Plc (NASDAQ:AMRN) reported fourth-quarter 2023 revenues of $74.71 million, down from $90.2 million, beating the consensus of $63.81 million.
The 17% Y/Y decline in revenues was driven primarily by a decrease in the volume of VASCEPA sales to Amarin’s customers in the United States, which were adversely impacted by generic availability in the United States.
U.S. net product revenue was $64.9 million, down $88 million a year ago. European net product revenue was $1.5 million, and the Rest of the World was $4.2 …